Susquehanna Fundamental Investments, LLC C4 Therapeutics, Inc. Transaction History
Susquehanna Fundamental Investments, LLC
- $2.14 Trillion
- Q1 2024
A detailed history of Susquehanna Fundamental Investments, LLC transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna Fundamental Investments, LLC holds 51,365 shares of CCCC stock, worth $309,730. This represents 0.02% of its overall portfolio holdings.
Number of Shares
51,365Holding current value
$309,730% of portfolio
0.02%Shares
3 transactions
Others Institutions Holding CCCC
# of Institutions
111Shares Held
49.5MCall Options Held
455KPut Options Held
429K-
State Street Corp Boston, MA7.15MShares$43.1 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT4.33MShares$26.1 Million0.19% of portfolio
-
Commodore Capital LP New York, NY3.41MShares$20.6 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.92MShares$17.6 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.46MShares$14.8 Million1.64% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $295M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...